# DRMA catalysts: Dermata Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/drma/catalysts

> Dermata Therapeutics, Inc. (DRMA) has no upcoming catalysts in this calendar. The latest recorded is the Dermata Therapeutics, Inc. earnings report, November 10, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Dermata Therapeutics, Inc. |
| Ticker | DRMA (Nasdaq) |
| SEC CIK | 1853816 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/drma |

## Cash runway

Cash $4.8M as of 2026-09-30; quarterly burn $2.6M; about 5.5 months of runway at that rate (XBRL company facts, accession 0001493152-26-050967).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2023 | [XYNGARI (DMT310) trial start](https://sec-api.dev/pdufa/dmt310) | DRMA |  | completed | "After receiving positive feedback and alignment with FDA from our End of Phase 2 meeting in June of 2023 we began enrolling patients in our XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne in December 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002885/drma_10k.htm)) |
| November 13, 2024 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_ex991.htm)) |
| 2025 | [Extension trial start](https://sec-api.dev/pdufa/extension) | DRMA |  | scheduled | "If the results of the STAR-1 trial are positive, in 2025, we plan on initiating the second XYNGARI™ Phase 3 clinical trial entitled STAR-2, followed by a long-term extension study as requested by FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002885/drma_10k.htm)) |
| Mar 2025 | [DMT410 topline data readout](https://sec-api.dev/pdufa/dmt410) | DRMA |  | scheduled | "After completing enrollment in November 2024, Dermata completed the last patient's last visit in March 2025 and expects to announce topline results from the STAR-1 study by the end of March 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm)) |
| March 17, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm)) |
| March 27, 2025 | [XYNGARI (DMT310) topline data readout](https://sec-api.dev/pdufa/dmt310) | DRMA |  | completed, positive | "SAN DIEGO, CA, March 27, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_ex991.htm)) |
| April 15, 2025 | [XYNGARI (DMT310) topline data readout](https://sec-api.dev/pdufa/dmt310) | DRMA |  | completed, met | "SAN DIEGO, CA, April 15, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_ex991.htm)) |
| May 14, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/ex99-1.htm)) |
| 2H 2025 | [XYNAGRI (xynagri) trial start](https://sec-api.dev/pdufa/xynagri) | DRMA |  | scheduled | "Based on the foregoing results, the Company plans to initiate the second XYNAGRI™ Phase 3 STAR-2 trial in the second half of 2025, which will be followed by an open-label extension study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_8k.htm)) |
| August 13, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm)) |
| late 2025 | [XYNGARI (DMT310) trial start](https://sec-api.dev/pdufa/dmt310) | DRMA | moderate-to-severe acne | scheduled | "With positive results from the STAR-1 trial, Dermata has begun the manufacturing campaign for the STAR-2 trial and plans to initiate the second Phase 3 trial of XYNGARI™ for the treatment of moderate-to-severe acne by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/ex99-1.htm)) |
| November 14, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/ex99-1.htm)) |
| March 26, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/ex99-1.htm)) |
| August 11, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/ex99-1.htm)) |
| Oct 2026 | [Dermata Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed, positive | "In October 2026, Dermata announced positive topline results from its completed cosmetic clinical study evaluating Tome Foundational Treatment in 31 participants over four weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226050964/ex99-1.htm)) |
| November 10, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Reports Financial Results for the Third Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226050964/ex99-1.htm)) |

## Drugs

- [XYNGARI (DMT310)](https://sec-api.dev/pdufa/dmt310): moderate-to-severe acne
- [DMT410](https://sec-api.dev/pdufa/dmt410): 
- [Extension](https://sec-api.dev/pdufa/extension): 
- [XYNAGRI (xynagri)](https://sec-api.dev/pdufa/xynagri): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/drma/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DRMA catalysts: Dermata Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/drma/catalysts

```bibtex
@misc{secapidev_companies_drma_catalysts_20261116,
  title        = {DRMA catalysts: Dermata Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/drma/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_drma_catalysts_20261116","title":"DRMA catalysts: Dermata Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/drma/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
